Charles River Laboratories announced the resignation of CFO Flavia H. Pease and the appointment of Michael G. Knell as interim CFO.
The company is conducting a search for a permanent CFO following Pease's departure.
2025 revenue and non-GAAP EPS guidance reaffirmed by the company.
CFO Transition
Flavia H. Pease resigns, Michael G. Knell appointed as interim CFO until successor named.
Guidance Reaffirmation
Company reaffirms its 2025 financial guidance for revenue and non-GAAP earnings per share.
- The CFO transition may bring temporary uncertainty but aims for a seamless transition.
- Reaffirmation of guidance signals confidence in the company's performance and strategic direction.
Despite the CFO transition, Charles River Laboratories remains focused on strategy execution and value creation for shareholders.